|
|
Office Locations:
|
One Sansome Street, Suite 3630
San Francisco, CA 94104
Phone: 415-801-8100
Fax: 650-854-9513
| |
|
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Founded in 1999, Versant Ventures currently manages over $1.9 billion in committed capital having recently raised its fifth fund. The firm specializes in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services, and healthcare information technology. Versant seeks large market opportunities and will not invest in a new company unless the opportunity has at least $500 million in annualized potential in the U.S. Versant has and will occasionally invest in later stage companies with the right attributes. Initial investments have been as small as $250 thousand and total investments have been as large as $30 million. The firm announced December of 2014 the close of Versant Venture Capital V L.P. at $305 million and in excess of the initial fund target of $250 million. Versant has $4.2 billion under management.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
